FDA Approves Emergency Use Authorization for Johnson & Johnson Single-Dose COVID-19 Vaccine
February 28th 2021Approximately 2 million doses of Johnson & Johnson's single-dose COVID-19 vaccine are ready to ship and supply is expected to sharply increase, with up to 20 million doses available by the end of March.
Read More
Study Finds Novel Mechanism of Resistance to Immunotherapy Targeting HER2
February 26th 2021As immunotherapies continue to show promise in more effectively combating several tumor types, many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.
Read More
Study: Low-Quality Diet During Pregnancy May Be Associated with Late-Childhood Obesity
February 26th 2021Researchers from University College Dublin, Ireland found that children of mothers who ate a higher quality diet during pregnancy that is low in inflammation-associated foods had a lower risk of obesity and lower body fat levels in late childhood than children whose mothers ate a lower quality diet during pregnancy that was high in inflammation-associated foods.
Read More
Study: Structured Exercise Program Benefited Men’s Artery Health, Not Testosterone Therapy
February 26th 2021The investigators said testosterone therapy may have some benefits for older men, but they did not find any benefits in artery function, which is a determinant of future cardiovascular risk.
Read More
Tip of the Week: Strategic Planning for Pharmacy Emergency Preparedness and Response Activities
February 26th 2021Pharmacy organizations have produced advisories to guide workflow and optimize services, yet there still exists a gap in further integration of pharmacists into public health and safety initiatives.
Read More
Study: Data Show Lower Daily Temperatures Lead to Higher Transmission of COVID-19
February 25th 2021SARS-CoV-2 belongs to a family of human coronaviruses, most of which are characterized by increased transmission in cooler, less humid months and decreased transmission in warmer, more humid months.
Read More
Expansion of Opaganib Global Phase 2/3 COVID-19 Study Planned for Patients With Severe COVID-19
February 24th 2021A global phase 2/3 study of opaganib in patients with severe COVID-19 is set to be expanded, following FDA review of the data from the phase 2 study of the drug and RedHill Biopharma’s receipt of its recommendations.
Read More
Study Estimates Financial Impact of COVID-19 as Insurers End Grace Period for Hospital Costs
February 24th 2021The estimate is based on a new analysis of out-of-pocket costs for influenza-related hospitalizations in 2018 that were paid by people with Medicare Advantage plans, which are Medicare plans run by private insurance companies.
Read More